Goldman Sachs’s Impax Laboratories, Inc. IPXL Stock Holding History

Goldman Sachs’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-50,000	Closed	-$2.14M	–	7486
2015 Q4	$2.14M	Buy	+50,000	New	+$2M	﹤0.01%	3566
2015 Q3	–	Sell	-135,000	Closed	-$6.2M	–	7622
2015 Q2	$6.2M	Buy	135,000 +45,000	+50%	+$2.14M	﹤0.01%	2774
2015 Q1	$4.22M	Buy	90,000 +20,000	+29%	+$796K	﹤0.01%	3064
2014 Q4	$2.22M	Buy	70,000 +20,000	+40%	+$585K	﹤0.01%	3740
2014 Q3	$1.19M	Buy	+50,000	New	+$1.28M	﹤0.01%	4439
2014 Q1	–	Sell	-59,200	Closed	-$1.49M	–	7022
2013 Q4	$1.49M	Buy	+59,200	New	+$1.32M	﹤0.01%	4368
2013 Q3	–	Sell	-50,000	Closed	-$997K	–	6786
2013 Q2	$997K	Buy	+50,000	New	+$888K	﹤0.01%	4402

Goldman Sachs's IPXL Position: Q2 2018 in Review

Goldman Sachs sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 1,752,374 shares — an estimated $34.1M sold.

Goldman Sachs first reported a position in IPXL in Q2 2013 and held it in 20 quarters. The position peaked at $40.5M in Q3 2017. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.

Goldman Sachs reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
Goldman Sachs sold 1,752,374 Impax Laboratories, Inc. shares in Q2 2018, an estimated $34.1M.
Goldman Sachs first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 20 quarters.
Goldman Sachs's Impax Laboratories, Inc. position peaked at $40.5M in Q3 2017.
1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.

Based on Goldman Sachs's 13F filing for Q2 2018, filed 14 Aug 2018.